MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers

At the Company’s Board of Directors’ meeting held on May 17,
2017, the Board approved an increase in the dollar value of the
annual equity grants for non-employee directors from $150,000 to
$170,000. All cash compensation arrangements remain the same. This
resulted in the need for an additional grant of 3,472 shares of
restricted stock to Luis Aguilar, who recently joined the Board in
March 2017, to bring his compensation in line with the other
non-employee directors.
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 17, 2017, MiMedx Group, Inc. held its 2017 Annual Meeting.
There were two proposals acted upon at the meeting. All nominees
for director were elected (Proposal 1) and Proposal 2 was approved.
The following is a description of each item and the votes cast for
each:
Proposal 1: The election of directors
For
Against
Abstain
Broker Non votes
Charles R. Evans
51,011,858
75,691
71,493
38,925,674
Charles E. Koob
45,887,932
5,216,382
54,728
38,925,674
Neil S. Yeston
50,611,028
465,416
82,598
38,925,674
Luis A. Aguilar
50,993,754
76,622
88,666
38,925,674
Proposal 2: Proposal to ratify the appointment of Cherry Bekaert
LLP as our independent registered public accounting firm for the
current fiscal year.
For
Against
Abstain
Total shares voted
88,814,205
652,337
618,174


About MIMEDX GROUP, INC. (NASDAQ:MDXG)

MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.

MIMEDX GROUP, INC. (NASDAQ:MDXG) Recent Trading Information

MIMEDX GROUP, INC. (NASDAQ:MDXG) closed its last trading session down -0.19 at 14.26 with 1,269,767 shares trading hands.